How Clonal Hematopoiesis Affects Breast Cancer Outcomes
Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) on tumor microenvironment and clinical outcomes in triple negative breast cancer
This study is looking at how certain changes in blood cells, which can happen as we age, might affect the way triple negative breast cancer grows and how well patients do, with the hope of finding better ways to help those diagnosed with this type of cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-11111153 on NIH RePORTER |
What this research studies
This research investigates the impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) on the tumor microenvironment and clinical outcomes in patients with triple negative breast cancer. It aims to understand how somatic mutations in blood and bone marrow cells, which can occur with age and exposure to stress, influence the behavior of tumors and the immune response. By analyzing clinical sequencing data and patient samples, the study seeks to uncover the relationship between CHIP and patient survival rates, potentially leading to improved management strategies for those affected.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer, particularly those over the age of 70 or who have undergone chemotherapy.
Not a fit: Patients with non-solid tumors or those without any evidence of CHIP may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better treatment strategies and improved survival outcomes for patients with triple negative breast cancer who have CHIP.
How similar studies have performed: Previous studies have indicated that understanding CHIP's role in cancer can lead to significant insights, suggesting that this research could build on established findings.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Reed, Sarah Camille — Vanderbilt University
- Study coordinator: Reed, Sarah Camille
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.